Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers.

Anu SharmaSumit K SubudhiJorge BlandoJorge ScuttiLuis VenceJennifer WargoJames P AllisonAntoni RibasPadmanee Sharma

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2018)

Anti-CTLA-4 immunotherapy does not deplete FOXP3+ cells in human tumors, which suggests that their efficacy could be enhanced by modifying the Fc portions of the mAbs to enhance Fc-mediated depletion of intratumoral regulatory T cells.See related commentary by Quezada and Peggs, p. 1130.

Keyphrases

regulatory t cells
dendritic cells
endothelial cells
immune response
cell cycle arrest
young adults
drug induced